Apollo Hospitals Enterprise Limited is India’s largest and most integrated healthcare provider, with a formidable presence across the entire healthcare ecosystem. The company operates a vast network of hospitals, clinics, diagnostic centers, and pharmacies, complemented by a rapidly growing digital platform, establishing a true omni-channel healthcare model. Its core business, Healthcare Services, anchors the enterprise with 76 hospitals and over 10,000 census beds, making it the largest pan-India hospital chain with a significant footprint in major metros like Chennai, Hyderabad, Delhi, and Mumbai, as well as numerous Tier-1 and Tier-2 cities.

Beyond tertiary care, Apollo has strategically expanded into out-of-hospital services through its subsidiary, Apollo Health & Lifestyle Ltd (AHLL). This segment focuses on organizing the largely unorganized primary care market, operating over 300 clinics, 2,400 diagnostic centers, and specialized facilities for dialysis, dental care, and birthing. This ensures Apollo captures the consumer early in their healthcare journey and maintains a continuum of care.

The third pillar of the enterprise is Apollo HealthCo, which combines the nation's largest offline pharmacy distribution network of over 7,100 stores with the Apollo 24|7 digital platform. This digital arm serves over 46 million registered users, offering virtual doctor consultations, online medicine delivery, e-health records, and online booking for hospital and diagnostic services. By integrating its physical assets with a robust digital interface, Apollo has created a comprehensive ecosystem designed to manage a patient's health from proactive wellness and primary consultation to complex surgical procedures and post-treatment support.

Official Website: http://www.apollohospitals.com/

• Consolidated Performance (Q3 FY26): The company reported strong financial results for the third quarter of fiscal year 2026.

• Revenue: Grew by 17% year-over-year (YoY) to ₹ 64,774 million.

• EBITDA: Increased by 27% YoY to ₹ 9,653 million, with the corresponding margin expanding to 14.9% from 13.8% in the prior year.

• Profit After Tax (PAT): Grew by 35% YoY to ₹ 5,023 million.

• Consolidated Performance (YTD Dec 25): The performance for the first nine months of the fiscal year was equally robust.

• Revenue: Grew by 15% YoY to ₹ 186,230 million.

• EBITDA: Increased by 22% YoY to ₹ 27,584 million.

• PAT: Grew by 34% YoY to ₹ 14,123 million.

• Segment Performance (Q3 FY26): All business segments contributed to the overall growth.

• Healthcare Services (Hospitals): Revenue grew 14% to ₹ 31,832 million with an EBITDA of ₹ 7,898 million, reflecting an 18% growth.

• Diagnostics & Retail Health (AHLL): Revenue grew 20% to ₹ 4,668 million, while EBITDA saw a substantial 39% increase to ₹ 476 million.

• Digital Health & Pharmacy (Apollo HealthCo): Revenue grew 20% to ₹ 28,274 million. EBITDA grew an impressive 126% to ₹ 1,279 million, signaling a strong improvement in operational efficiency.

• Balance Sheet: As of December 2025, the company maintains a strong financial position with a consolidated net debt of -₹2,996 million, indicating a net cash position. This is supported by cash and cash equivalents of ₹28,614 million against a gross debt of ₹25,618 million (excluding lease liabilities).

The company delivered strong, double-digit growth in revenue and profits across all its business segments, coupled with margin expansion and a healthy net cash position on its balance sheet.

• Integrated Omni-Channel Ecosystem: Apollo's primary uniqueness lies in its fully integrated healthcare model. It combines a vast physical network of hospitals, clinics, and pharmacies with a comprehensive digital platform (Apollo 24|7), creating a seamless patient experience from virtual consultation to in-person treatment and medicine delivery.

• Unmatched Scale and Pan-India Reach: The company operates the largest hospital chain in India, with a presence in major metros and smaller cities. This is supplemented by over 7,100 pharmacy outlets and more than 2,400 diagnostic centers, providing an unparalleled physical footprint that builds strong brand recall and accessibility.

• Full Spectrum of Care: Apollo offers a complete continuum of care. This starts with primary care at its clinics, extends to specialized diagnostics, covers complex tertiary and quaternary care at its hospitals (including advanced treatments like proton therapy), and provides post-treatment support through its extensive pharmacy network.

• Data and Technology Leverage: The Apollo 24|7 platform, with over 46 million registered users, serves as a powerful tool for customer acquisition and engagement. The platform utilizes AI-enabled technologies, including a Clinical Intelligence Engine, to enhance service delivery and create a moat against competitors focused on single verticals.

Apollo's key differentiator is its ability to operate as a cohesive, omni-channel healthcare ecosystem at a scale that is difficult to replicate, allowing it to capture and retain customers across their entire healthcare journey.

• Healthcare Services Growth Drivers: The hospital division's 14% revenue growth in Q3 FY26 was driven by a combination of factors.

• Volume Growth: In-patient discharges grew by 4% YoY.

• ARPP Growth: Average Revenue per Patient (ARPP) increased by 11% to ₹ 180,917. This was fueled by a 3% price increase and a significant 7% improvement in case mix, indicating a focus on more complex, higher-margin procedures.

• Diagnostics & Retail Health (AHLL) Growth: This segment's 20% revenue growth was primarily powered by the diagnostics business.

• Diagnostics Revenue: Grew by an impressive 46% YoY in Q3 FY26.

• Wellness Segment: The preventive wellness business within diagnostics grew by 32% in the nine-month period, contributing 18% of the segment's revenue.

• Digital Health & Pharmacy (HealthCo) Growth: The HealthCo segment delivered 20% revenue growth, with its digital platform showing strong traction.

• Platform GMV: Grew by 28% YoY in Q3 FY26 to ₹ 5,250 million.

• User Engagement: Online pharmacy transactions grew 23% YoY, and the number of transacting users grew by 25% YoY.

Growth is well-diversified across all business segments, supported by a healthy mix of increased patient volumes, higher-value treatments, and rapid expansion in the high-potential diagnostics and digital health verticals.

• Organizing the Unorganized Sector: A significant opportunity exists in the diagnostics and primary care space. The document notes that organized chains represent only about 30% of the pathology market, leaving substantial room for a trusted brand like Apollo to gain market share from smaller, unorganized players.

• Expansion of Digital Services: The Apollo 24|7 platform creates opportunities to cross-sell and up-sell new services. The company is actively expanding its insurance business across multiple brands and products, leveraging its large user base to enter adjacent financial services markets.

• Telehealth and Remote Care: The digital platform expands Apollo's reach into distant and underserved regions. This allows the company to tap into a new customer base that previously had limited access to quality healthcare, offering services like tele-consultancy and tele-emergency.

• Deepening Hospital Penetration: There is an opportunity to drive higher volumes to the hospital network through the digital platform. By focusing on multi-specialty coverage and joint marketing offerings, the digital channel can act as a significant lead generator for the core hospital business.

The company is strategically positioned to capture growth by formalizing the unorganized healthcare market, expanding its service offerings through its digital platform, and using technology to penetrate new geographies.

• Current Capacity Utilization:

• Overall Occupancy: The hospital network operated at a 67% occupancy rate in Q3 FY26.

• Regional Variation: Metro hospitals demonstrated higher utilization at 71%, while non-metro facilities operated at 62%, indicating room for operational leverage, particularly in non-metro regions.

• Capital Expenditure (Capex) and Expansion Plan:

• Bed Addition: The company has a clearly defined plan to add approximately 4,400 capacity beds (~3,600 census beds) over the next five years.

• Total Investment: The total project cost for this expansion is estimated at ~₹ 8,200 crores, with a balance of ~₹ 5,400 crores yet to be spent.

• Phased Rollout: The expansion is structured in two phases:

• FY26 - FY27: Commissioning of ~1,660 census beds.

• FY29 - FY30: Commissioning of ~1,970 census beds.

• Expansion Strategy: The growth will be achieved through a mix of greenfield projects (e.g., Mumbai, Chennai), brownfield expansions at existing facilities, and hospital asset acquisitions (e.g., Gurgaon, Pune).

The company is operating with sufficient room to improve occupancy while simultaneously executing a significant, well-structured capex plan of ₹8,200 crores to add over 3,500 beds and secure long-term growth.

• Corporate Restructuring of Apollo HealthCo: The most significant strategic initiative is the proposed demerger and listing of the Apollo HealthCo business.

• Transaction Structure: The plan involves a composite scheme to demerge the omnichannel pharmacy distribution business and the Apollo 24|7 platform from the parent company, followed by an amalgamation with Keimed Private Limited.

• Outcome: This will create a new, separately listed entity ("New Co") that will house the entire pharmacy, digital, and distribution business.

• Timeline: The listing of the new entity is estimated to be completed by Q4 FY27, pending shareholder and regulatory approvals.

• Financial Targets for New Entity: The company has set an ambitious target for the combined HealthCo and Keimed entity. It expects to achieve an annualized revenue run rate of ₹ 250 billion in Q4 FY27 with a 7% EBITDA margin.

• Continued Network Expansion: The company will continue to add to its physical network, with 185 new pharmacy stores added in Q3 FY26 and a clear roadmap for hospital bed additions through FY30.

The primary future plan is a major corporate restructuring to unlock value by listing the high-growth HealthCo business as a separate entity by Q4 FY27, with clear and ambitious financial targets.

• Consolidated Margin Profile: Consolidated EBITDA margin improved to 14.9% in Q3 FY26 from 13.8% a year ago, driven by operational efficiencies.

• Segment Margin Analysis:

• Healthcare Services: Remains the most profitable segment with a strong and stable EBITDA margin of 24.8%.

• AHLL: Reported an EBITDA margin of 10.2%, showing improvement from 8.8% in the prior year.

• Apollo HealthCo: EBITDA margin stood at 4.5%, a significant improvement from 2.4% last year. The profitability of this segment is impacted by investments in the digital platform.

• Path to Profitability for Digital Business: The digital segment is showing a clear trend towards profitability.

• Reduced Cash Burn: The digital platform's cash loss narrowed by 61% YoY, from ₹ 758 million in Q3 FY25 to ₹ 292 million in Q3 FY26.

• Core Profitability: The HealthCo segment's EBITDA margin before accounting for 24|7 operating costs and ESOPs is a healthy 8.9%, indicating the underlying pharmacy distribution business is robustly profitable.

Consolidated margins are expanding, led by the highly profitable hospital business, while the HealthCo segment demonstrates a clear and rapid trajectory towards profitability as digital investments scale and operational losses narrow significantly.

• Execution Risk: The company has laid out an ambitious ₹8,200 crore expansion plan to add over 3,500 beds. This large-scale capex program carries inherent execution risks related to project timelines, cost overruns, and the successful ramp-up of new facilities.

• Integration Risk: The proposed amalgamation of Keimed Private Limited with the Apollo HealthCo business is a large-scale integration. Successfully merging operations, corporate cultures, and technology platforms will be critical to realizing the projected synergies and financial targets.

• Regulatory Changes: The healthcare sector is subject to stringent regulations. An exceptional item of ₹192 million was recorded due to the New Labour Code, highlighting how changes in government policy can directly impact financial liabilities and profitability.

• Market and Operational Factors: As noted in the forward-looking statements, the business is subject to various market risks and assumptions. Future performance could be impacted by factors such as changes in patient volumes, pricing pressures, and the competitive landscape.

Key risks are centered on the successful execution of the company's large-scale expansion and integration plans, alongside the ever-present impact of the evolving regulatory environment on its operations.

• Advanced Clinical Achievements: The hospital division continues to strengthen its clinical excellence.

• Gene Therapy: Successfully treated a 13-month-old with Spinal Muscular Atrophy (Type 1) using advanced gene therapy, showcasing its ability to adopt cutting-edge medical science.

• Robotic Surgery: Launched an advanced multi-robot surgery center in Delhi.

• New Centers of Excellence: Opened a dedicated center for Parkinson’s & DBS care in Chennai.

• Technology and Innovation in AHLL: The diagnostics and retail health segment is leveraging technology to improve services.

• AI in Diagnostics: Implemented an AI-based dental radiology tool across clinics to improve diagnostic accuracy.

• Test Menu Expansion: Expanded its high-end test offerings to include advanced genetic and molecular diagnostics like chromosomal microarrays and NGS-based HLA typing.

• HealthCo Operational Enhancements:

• Efficient Customer Acquisition: Driving new user acquisition through an omnichannel strategy with marketing spend significantly lower than the previous year.

• Service Expansion: Boosted diagnostic Gross Merchandise Value (GMV) by expanding into 18 new cities and introducing new collection channels via its pharmacy stores.

The company is actively pushing the boundaries of clinical innovation with advanced therapies and robotics, while embedding technology like AI into its diagnostic services and optimizing its digital marketing strategies for efficient growth.